Anti-IL 13 antibodies and uses thereof
View Patent ↗The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
1. A monoclonal antibody that specifically binds human interleukin-13 (“IL-13”), wherein said antibody comprises a variable heavy chain region comprising complementarity determining regions CDRH 1, CDRH2 and CDRH3 having the amino acid sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the amino acid sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.
2. The antibody of claim 1 , wherein said antibody comprises the amino acid sequence of SEQ ID NO: 4, and the amino acid sequence of SEQ ID NO: 3.
3. The antibody of claim 1 , wherein said antibody comprises the amino acid sequence of SEQ ID NO: 142, and the amino acid sequence of SEQ ID NO: 143.
4. The antibody of claim 1 , wherein the antibody is an IgG antibody.
5. The antibody of claim 4 , wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
6. The antibody of claim 1 , wherein the antibody is humanized.
7. The antibody of claim 1 , wherein the antibody is an antibody fragment.
8. The antibody of claim 1 , wherein the antibody is a monovalent antibody, a multispecific antibody, a chimeric antibody, a single chain antibody, a Fab fragment or a F(ab′) fragment.
9. A pharmaceutical composition comprising the antibody of claim 1 , 2 , 3 , 4 , 5 , 6 , or 8 .
10. A pharmaceutical composition comprising the antibody of claim 7 .
11. A hybridoma cell line that produces the antibody of claim 1 .
12. A monoclonal antibody that specifically binds human IL-13, wherein said antibody comprises the amino acid sequence of an antibody produced by a hybridoma designated with American Type Culture Collection (“ATCC”) accession number PTA-5657.
13. A monoclonal antibody that specifically binds human IL-13, wherein said antibody is produced by a method comprising the step of expressing the antibody from a host cell, wherein said antibody is the antibody of claim 1 , 3 , or 6 .
14. The monoclonal antibody of claim 13 , wherein said method further comprises purifying the antibody from said host cell.
15. The monoclonal antibody of claim 13 , wherein the host cell is a mammalian cell.
16. The monoclonal antibody of claim 14 , wherein the mammalian cell is a Chinese hamster ovary (CHO) cell.
17. The monoclonal antibody of claim 1 , 3 , or 6 , wherein said antibody is conjugated to a molecule.
18. The monoclonal antibody of claim 17 , wherein the molecule is a polypeptide or a detectable substance.
19. The monoclonal antibody of claim 12 , wherein the antibody is an IgG antibody.
20. The monoclonal antibody of claim 13 , wherein the antibody is an IgG antibody.
21. The monoclonal antibody of claim 19 , wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
22. The monoclonal antibody of claim 20 , wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
23. The monoclonal antibody of claim 3 , wherein the antibody is a monovalent antibody, a multispecific antibody, a single chain antibody, a Fab fragment, is a F(ab′) fragment.
24. The monoclonal antibody of claim 13 , wherein the antibody is a monovalent antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a Fab fragment, or a F(ab′) fragment.
25. The monoclonal antibody of claim 23 , wherein the antibody is a multispecific antibody that is a bispecific antibody.
26. The monoclonal antibody of claim 24 , wherein the antibody is a multispecific antibody that is a bispecific antibody.
27. The monoclonal antibody of claim 8 , wherein the antibody is a multispecific antibody that is a bispecific antibody.
28. A pharmaceutical composition comprising the monoclonal antibody of claim 13 .
29. A pharmaceutical composition comprising the monoclonal antibody of claim 19 .
30. A pharmaceutical composition comprising the monoclonal antibody of claim 20 .
31. A pharmaceutical composition comprising the monoclonal antibody of claim 21 , 23 , or 25 .
32. A pharmaceutical composition comprising the monoclonal antibody of claim 22 .
33. A pharmaceutical composition comprising the monoclonal antibody of claim 24 .
34. A pharmaceutical composition comprising the monoclonal antibody of claim 26 .
35. A pharmaceutical composition comprising the monoclonal antibody of claim 27 .
36. The hybridoma cell line of claim 11 , which comprises a hybridoma designated with ATCC accession number PTA-5657.
37. The monoclonal antibody of claim 1 , further comprising human framework regions.